Outlook Therapeutics Inc. Stock News

Live fireside chat with C. Russell Trenary, President and CEO of Outlook Therapeutics on Tuesday, September 28 at 2:00 PM ET Live fireside chat with C. Russell Trenary, President and CEO of Outlook Th

Shares of Outlook Therapeutics (NASDAQ:OTLK) moved higher by 2.8% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 133.33% year over year to

Trading penny stocks is more popular than ever; here's 3 you need to know about The post Are Penny Stocks Worth It? 3 to Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Informat

If you want to travel on the speculative side of the market, these penny stocks might have the right stuff for you to strike it rich. The post 7 Penny Stocks That Have That ‘Get Rich' Potential appe

Biotech penny stocks are heating up right now; here's 3 to watch The post Best Biotech Penny Stocks For Your Small-Caps Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Infor

Investors are excited about the potential of the drugmaker's experimental wet AMD treatment.

H.C. Wainwright raised the price target on Outlook Therapeutics Inc (NASDAQ:OTLK) to $6 from $5 and reiterated a Buy rating. The Company announced "exceptionally strong" data that showed Lytenava'

The stock price of Outlook Therapeutics Inc (NASDAQ: OTLK) increased by over 30% pre-market. This is why it happened.

Outlook Therapeutics Inc (NASDAQ: OTLK) stock is trading higher in premarket session in reaction to positive top-line results from Phase 3 NORSE TWO trial evaluating ONS-5010 / LYTENAVA (bevacizuma

ISELIN, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of

Penny stocks are ready for a new month; should you watch these 3? The post Hot Penny Stocks to Buy?

There is something uniquely exciting about being the first company to bring a much-needed product to market. Outlook Therapeutics Inc (NASDAQ:OTLK) is hoping to become the first and only company to c

iBio (NYSE: IBIO) shares are trading lower Wednesday after the company reported second-quarter earnings results. iBio's main area of business is plant-based protein expression technologies for vaccine

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Some insiders have been taking advantage of secondary offerings recently.

MONMOUTH JUNCTION, N.J., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved op